Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines

Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines

IntroductionCertain HLA variants are associated with an increased risk of hypersensitivity reactions to specific drugs. Both the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) have issued actionable HLA gene – drug interaction guideline...

Full description

Bibliographic Details
Main Authors:	Lisanne E. N. Manson, Jesse J. Swen, Henk-Jan Guchelaar
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-09-01
Series:	Frontiers in Pharmacology
Subjects:	HLA genes pharmacogenomics hypersensitivity antiepileptic drugs abacavir allopurinol
Online Access:	https://www.frontiersin.org/article/10.3389/fphar.2020.567048/full

Similar Items

Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany
by: Wolf E, et al.
Published: (2010-04-01)

Jämförelse mellan två analyskit för typning av det humana leukocytantigenet HLA-B*57
by: Håkansson, Cornelia
Published: (2017)

HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects
by: Catherine Butkus Small, et al.
Published: (2017-04-01)

Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines
by: Heshu Abdullah-Koolmees, et al.
Published: (2021-01-01)

HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: a cohort study
by: Karam Mounzer, et al.
Published: (2019-01-01)

Prevalence of HLA-B*57:01 allele in HIV-infected patients in a university hospital in Tehran
by: Mahboobeh Haji-Abdolbaghi, et al.
Published: (2014-04-01)

HLA-B allele and haplotype diversity among Thai patients identified by PCR-SSOP: evidence for high risk of drug-induced hypersensitivity
by: CHONLAPHAT eSUKASEM
Published: (2015-01-01)

HLA-B*5701 frequency in Chilean HIV-infected patients and in general population
by: Helena Poggi, et al.

Clinical evaluation of a substitute of HLA-B*58:01 in different Chinese ethnic groups
by: Xinju Zhang, et al.
Published: (2018-08-01)

HLA-B*57:01 allele prevalence in treatment-Naïve HIV-infected patients from Colombia
by: Ernesto Martínez Buitrago, et al.
Published: (2019-09-01)

Clinical Usefulness of HLA-B∗58:01 Genotyping in Gouty Arthritis
by: Carrel Ka Lung Yu, et al.
Published: (2019-07-01)

Applying Next-Generation Sequencing Platforms for Pharmacogenomic Testing in Clinical Practice
by: Alireza Tafazoli, et al.
Published: (2021-08-01)

Screening do alelo HLA-B*5701 em associação a hipersensibilidade ao abacavir em pacientes HIV positivos do estado de Mato Grosso
by: Araújo, Claudinéia de [UNIFESP]
Published: (2015)

Adverse drug reactions triggered by the common HLA-B*57:01 variant: virtual screening of DrugBank using 3D molecular docking
by: George Van Den Driessche, et al.
Published: (2018-01-01)

Technologies for Pharmacogenomics: A Review
by: Maaike van der Lee, et al.
Published: (2020-12-01)

Prevalence of human leukocyte antigen HLA-B*57:01 in individuals with HIV in West and Central Africa
by: Malewe Kolou, et al.
Published: (2021-07-01)

Drug Induced Hypersensitivity and the HLA Complex
by: Munir Pirmohamed, et al.
Published: (2010-12-01)

HLA Pharmacogenetic Markers of Drug Hypersensitivity in a Thai Population
by: Nontaya Nakkam, et al.
Published: (2018-08-01)

HLA-B*58:01 for allopurinol-induced cutaneous adverse drug reactions: Implication for clinical interpretation in Thailand
by: Chonlaphat Sukasem, et al.
Published: (2016-07-01)

The HLA-A*31:01 allele: influence on carbamazepine treatment
by: Yip VLM, et al.
Published: (2017-01-01)

Drug Use in Denmark for Drugs Having Pharmacogenomics (PGx) Based Dosing Guidelines from CPIC or DPWG for CYP2D6 and CYP2C19 Drug–Gene Pairs: Perspectives for Introducing PGx Test to Polypharmacy Patients
by: Niels Westergaard, et al.
Published: (2020-01-01)

Association between the HLA-B*1502 gene and mild maculopapular exanthema induced by antiepileptic drugs in Northwest China
by: Nilupaer Shafeng, et al.
Published: (2021-09-01)

Assessing the Implementation of Pharmacogenomic Panel-Testing in Primary Care in the Netherlands Utilizing a Theoretical Framework
by: Cathelijne H. van der Wouden, et al.
Published: (2020-03-01)

A Novel Allele-Specific PCR Protocol for the Detection of the HLA-C*03:02 Allele, a Pharmacogenetic Marker, in Vietnamese Kinh People
by: Pham TTH, et al.
Published: (2021-02-01)

Allopurinol-induced Severe Hypersensitivity with Acute Renal Failure
by: I-Hung Chen
Published: (2005-05-01)

Drug reaction with eosinophilia and systemic symptoms: A drug-induced hypersensitivity syndrome with variable clinical features
by: Yi-Chun Chen, et al.
Published: (2013-12-01)

Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review
by: Sylvia D. Klomp, et al.
Published: (2020-09-01)

Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The Netherlands
by: P. C. D. Bank, et al.
Published: (2019-06-01)

HLA-B*13:01 as a Risk Allele for Antiepileptic Drugs-Induced Cutaneous Adverse Reactions: Higher Risk for Cross-Reactivity?
by: Fu-Li Min, et al.
Published: (2019-06-01)

Association Between HLA Genotype and Cutaneous Adverse Reactions to Antiepileptic Drugs Among Epilepsy Patients in Northwest China
by: Xu Wang, et al.
Published: (2019-01-01)

The Mechanistic Differences in HLA-Associated Carbamazepine Hypersensitivity
by: Gwendolin S. Simper, et al.
Published: (2019-10-01)

Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple <i>DPYD</i> Variants
by: Carin A. T. C. Lunenburg, et al.
Published: (2018-11-01)

HLA-B and HLA-C Differ in Their Nanoscale Organization at Cell Surfaces
by: Philippa R. Kennedy, et al.
Published: (2019-01-01)

Analysis of HLA-A, HLA-B and HLA-DRB1 allelic frequencies in tertiary care from Telangana and Andhra Pradesh
by: Radhika Chowdary, et al.
Published: (2014-06-01)

Interactions between HLA-G and HLA-E in physiological and pathological conditions
by: Fabio eMorandi, et al.
Published: (2014-08-01)

HLA-H: Transcriptional Activity and HLA-E Mobilization
by: François Jordier, et al.
Published: (2020-01-01)

<it>HLA-DQA1</it> and <it>HLA-DQB1</it> in Celiac disease predisposition: practical implications of the HLA molecular typing
by: Megiorni Francesca, et al.
Published: (2012-10-01)

The HLA-Cw6 Dilemma: Is It Really an Outcome Predictor in Psoriasis Patients under Biologic Therapy? A Monocentric Retrospective Analysis
by: Martina Burlando, et al.
Published: (2020-09-01)

DIFFERENTIAL IMPACT OF HLA-A, HLA-B AND HLA-DR COMPATIBILITY ON THE RENAL ALLOGRAFT SURVIVAL
by: V. Y. Abramov, et al.
Published: (2012-09-01)

Association of Protective HLA-A With HLA-B∗27 Positive Ankylosing Spondylitis
by: Jessika Nordin, et al.
Published: (2021-07-01)